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Abstract
Cystin is a novel cilia-associated protein that is disrupted in the cpk mouse, a well-characterized mouse model of autosomal
recessive polycystic kidney disease (ARPKD). Interestingly, overexpression of the Myc gene is evident in animal models of
ARPKD and is thought to contribute to the renal cystic phenotype. Using a yeast two-hybrid approach, the growth
suppressor protein necdin, known to modulate Myc expression, was found as an interacting partner of cystin. Deletion
mapping demonstrated that the C-terminus of cystin and both termini of necdin are required for their mutual interaction.
Speculating that these two proteins may function to regulate gene expression, we developed a luciferase reporter assay and
observed that necdin strongly activated the Myc P1 promoter, and cystin did so more modestly. Interestingly, the necdin
effect was significantly abrogated when cystin was co-transfected. Chromatin immunoprecipitation and electrophoretic
mobility shift assays revealed a physical interaction with both necdin and cystin and the Myc P1 promoter, as well as
between these proteins. The data suggest that these proteins likely function in a regulatory complex. Thus, we speculate
that Myc overexpression in the cpk kidney results from the dysregulation of the cystin-necdin regulatory complex and
c-Myc, in turn, contributes to cystogenesis in the cpk mouse.
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Introduction
Polycystic kidney disease (PKD) is a group of genetic disorders
characterized by the progressive development of renal cysts,
ultimately leading to end-stage renal disease [1]. PKD is further
defined by inheritance as either autosomal dominant polycystic
kidney disease (ADPKD) or autosomal recessive polycystic kidney
disease (ARPKD). ADPKD occurs with an estimated prevalence
of 1:400 to 1:1,000 live births. Symptoms may manifest at any time
in life and are characterized by cyst formation in ductal organs
(particularly the kidney and liver), in addition adults may present
with gastrointestinal, cardiovascular, and musculoskeletal abnor-
malities. Overall, ADPKD accounts for ,8% of cases of end-stage
renal disease [2–5]. Mutations in one of two genomic loci, PKD1
(encoding polycystin 1, PC-1) or PKD2 (encoding polycystin 2, PC-
2), are associated with ADPKD phenotypes that are similar in
clinical presentation [6,7]. Approximately 85% of ADPKD cases
are caused by mutations in the PKD1 gene, and the remaining
15% can be attributed to mutations in the PKD2 gene [8–12].
While the functions of each protein are not fully understood, it has
been demonstrated in vitro that these proteins associate in the
membrane of the primary apical cilia as a mechano-sensitive
complex that regulates calcium signaling [13,14].
In contrast to the dominant form of PKD, ARPKD is much less
prevalent and generally more severe. ARPKD occurs once in
20,000 live births and is characterized by cystic kidneys and
congenital hepatic fibrosis with a high rate of mortality in affected
newborns [12,15]. In a subset of patients, the disease phenotype
predominantly involves portal hypertension or cholangitis [15,16].
Genetic analysis has shown that mutations in PKHD1, which
encodes the fibrocystin/polyductin (FPC) protein, cause ARPKD
[17–19]. Initial studies suggested that disease severity correlated
with the type of mutation [12,17–21], however, this association
has not been substantiated [22,23]. Indeed, mice with mutations in
Pkhd1 do not display phenotypes similar to ARPKD. In sum, the
molecular functions of FPC are poorly defined. However, like
many of the other ciliary proteins, FPC appears to play a role in
the structural integrity of cilia, as well as facilitating ductal
epithelial differentiation, by participating in multiple cellular
events, such as proliferation, secretion, apoptosis, and terminal
differentiation [24–28]. It is also increasingly evident that FPC
interacts with PC-2 at the cilium [29–31].
Among the mouse models for ARPKD, the congenital
polycystic kidney (cpk) mouse with a mutation in cystin, was the
first to be described and remains the most extensively character-
ized [32–34]. The renal phenotype of the cpk mouse is strikingly
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similar to human ARPKD despite being genetically distinct from
the human disorder [35,36]. Our group has demonstrated that the
gene Cys1 encodes cystin, a novel lipid-microdomain associated
protein that co-localizes with PC-1, PC-2, and Ift88 in the primary
apical cilia of renal epithelia cells [37–39]. Recent studies have
demonstrated that Cys1 is a target of the transcriptional complex
that is regulated by the hepatic nuclear factor (HNF) transcription
factors [40–42]. However, any role cystin plays in human disease
or cystogenesis remains unclear.
In the present study, we performed yeast two-hybrid (Y2H)
screening and identified putative interacting partners of cystin.
Experiments demonstrated that the growth suppressor and
transcriptional regulator necdin interacts with cystin. Necdin has
been shown to interact with several cystogenic related proteins and
may play a role in PKD. Using multiple approaches, such as
luciferase reporter assays, chromatin immunoprecipitation (ChIP),
and electrophoretic mobility shift assays (EMSA), we determined
that cystin forms a regulatory complex with necdin and modulates
the expression of the c-Myc gene, Myc. Interestingly, overexpres-
sion of Myc is well documented in Cys1cpk/cpk kidneys [43,44]. We
speculate that the loss of cystin function or the disruption of this
regulatory complex results in the overexpression of Myc, which
alters downstream targets and contributes to cystogenesis in the cpk
mouse model of ARPKD.
Results
Yeast two-hybrid screening
In previous studies, we showed that cystin, the protein product
of Cys1 that is mutated in the cpk mouse, is localized within the
ciliary membrane of kidney epithelial cells. Interestingly, a
myristoylation mutant termed cystinG2A, was shown to accumulate
in the nucleus [38]. This suggested that cystin exits the cilium and
may function in the nucleus in certain physiological conditions.
Thus, we sought to identify cystin interacting partners by yeast
two-hybrid screening. We cloned full-length mouse cystin and
performed two rounds of Y2H screening using an embryonic day
17 mouse cDNA library (Table 1). Using highly stringent selection,
we identified several putative interacting partners (data not
shown). Necdin was of particular interest because it is known to
interact with p53 and participate in gene regulation. In order to
eliminate any false positives, and to validate the results, we
reversed the bait and prey pairs and re-screened the interaction
(Table 2). This further confirmed that in yeast, the interaction
between cystin and necdin was genuine.
In order to define the interaction domains in both cystin and
necdin, we made a series of deletion constructs (lower panel of
Figure 1A and 1B), and evaluated their interaction in the same
Y2H system. The data showed that the deletion of C-terminal 25
amino acids (aa) of cystin, cystin-C25, abolished its ability to
interact with necdin. Interestingly, the carboxy terminal fragment
of cystin, alone, is enough to bind necdin (Figure 1A, upper panel).
Regarding necdin, there appears to be two cystin interaction
domains on either side of the melanoma antigen (MAGE) domain
within aa 71 to 305 (Figure 1B, lower panel). Combined with the
Y2H results, we conclude that the cystin and necdin specifically
interact.
Cystin interacts with necdin
Following the Y2H screening, we used GST pull-downs and co-
immunoprecipitation to verify the interaction between cystin and
necdin in a mammalian system. We cloned full-length cystin into a
GST vector and full-length necdin into a myc vector. These
constructs were co-transfected into COS-7 cells and grown for
48 hours before lysis. Under the same binding and washing
conditions, myc-necdin was efficiently pulled-down by GST-cystin
(Figure 2A, left panel, arrowhead), while GST alone did not
(Figure 2A, lane 3). The lysates and elution were probed with GST
as both a transfection and loading control (Figure 2A, lanes 5-8).
Co-immunoprecipitation experiments were performed for
further validation. Full-length cystin and necdin were cloned into
an HA and myc vector, respectively, and co-transfected into COS-
7 cells. The cell lysates were immunoprecipitated with an HA
antibody and probed with the myc antibody. As expected, HA-
cystin interacted strongly with myc-necdin (Figure 2B, lane 4)
while HA alone did not (Figure 2B, lane 3). The lysates and
elutions were also probed with a cystin antibody, to act as both a
transfection and loading control (Figure 2B, right panel). Taken
together, the data show that cystin interacts with necdin in yeast as
demonstrated by Y2H, and in mammalian cells by GST and co-
immunoprecipitation.
Necdin and cystin are expressed in mouse kidney
epithelial cells
Following confirmation that necdin physically interacts with
cystin in vitro, we explored whether necdin and cystin were
expressed in the same cell types, specifically mIMCD-3 (mouse
inner medulla collecting ducts) cells. In order to evaluate the
expression of the endogenous cystin and necdin at the transcript
level, we isolated total RNA from confluent mIMCD-3 cells and
performed RT-PCR. The specific products of cystin (207 bp) and
necdin (632 bp) (Figure 3A) were amplified and verified by
nucleotide sequence analysis (data not shown). In addition, we
assessed endogenous necdin and cystin at the protein level.
Cellular fractions were prepared from confluent mIMCD-3 cells
grown in 10 cm plates. Western blots with our cystin antibody
(70053 [37]) showed that cystin is highly expressed in confluent
mIMCD-3 cells. The target band of cystin, ,25 kD, was
specifically detected in the cytoplasm, membrane, and nucleus
(Figure 3B). Necdin was only detectable in the nucleus and not in
the cytoplasm under these conditions (Figure 3C, left panel,
arrowhead) and is robustly expressed, exogenously, in whole cell
lysates (Figure 3C, right panel).
Cystin has a functional nuclear localization signal (NLS)
Bioinformatic analysis predicted that cystin contains two
nuclear localization signals (termed NLS1 and NLS2, Figure 4A
[38]). Using a subcellular fractionation approach, we examined
whether NLS1 was functional using modified versions of cystin.
First, we performed subcellular fractionation (n = 5 experiments) in
wild type mIMCD-3 cells to assess the reproducibility of the






p53+LgT and Lam+LgT were used as positive and negative controls,
respectively for protein interaction. Necdin was identified from a cDNA library
as a full-length cystin binding partner. LgT: large T-antigen; Lam: human lamin
C. pGBKT7 is a bait vector containing the GAL4 DNA binding domain; pGADT7
and pACT2 are prey vectors containing the GAL4 activation domain.
doi:10.1371/journal.pone.0083062.t001
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technique and performed western blotting to confirm that there
was no contamination among fractions (Figure 4D). Stably-
transfected cell lines were then processed in parallel to determine
the subcellular localization of the cystin::GFP variants. For each
stably-transfected mIMCD-3 cell line, western blotting was
performed after fractionation and the relative levels of cystin
therein were assessed by densitometry. The bars represent the
relative amount of cystin in each fraction (total sums to 100%). In
Figure 4A, the fractions are cytosol (1), membrane (2), nuclear (3)
and cytoskeleton (4). Cystinwt::GFP was associated with the mem-
brane but was also detected in the cytoplasm. However, less than
10% was found in the nucleus (Figure 4A). The cystinn1-20::GFP
construct lacking both the NLS1 and myristoylation domains was
observed largely in the cytoplasm and was strikingly decreased in
the nuclear fraction (Figure 4B). In contrast, the cystinG2A::GFP
protein was not dramatically increased in the cytoplasm, despite
the fact that it was unable to associate with the membrane.
However this variant was substantially increased in the nucleus,
Table 2. Vector switch to eliminate false positive clones.
SD/-Ade-His-Leu-Trp+3-AT (mM) SD/-Leu-Trp
0 2.5 5 7.5 10 15
pGBKT7-p53+pGADT7-lgT + + + + + + +
pGBKT7-Lam+pGADT7-lgT – – – – – – +
pGBKT7+pGADT7-cystin – – – – – – +
pGBKT7-necdin+pGADT7 – – – – – – +
pGBKT7-necdin+pGADT7-cystin + + + + + + +
p53+LgT and Lam+LgT were used as positive and negative controls, respectively. Necdin was switched from the prey vector (pGADT7) to the bait vector (pGBKT7). The
new constructs were re-tested and their interactions were validated. 3-AT: 3-amino-1,2,4-triazole, a competitive inhibitor of the His3 protein.
doi:10.1371/journal.pone.0083062.t002
Figure 1. An interaction between cystin and necdin was identified in a yeast two-hybrid screen. (A) After the initial unbiased screen full-
length cystin was cloned into a prey vector, while necdin was cloned into a bait vector. Both were co-transformed and spread onto control SD/-Leu-
Trp (data not shown) and selective SD/-Ade-His-Leu-Trp plates. A series of deleted cystin constructs were co-transformed with full-length necdin to
isolate the necdin-interacting domain. Y2H positive (pGADT7-LgT+pGBKT7-p53) and negative controls (pGADT7-LgT+pGBKT7-Lam) are also shown. A
scheme of the interactions between the versions of cystin and necdin are shown at the lower panel. The C-terminal 25 aa of cystin are required for its
interaction with necdin. (B) A series of necdin constructs (prey) were co-transformed along with full-length cystin (bait) to determine the cystin-
interacting domain. A scheme of the interaction between the versions of necdin and cystin are shown in the lower panel. Necdins cystin interaction
domain lies within aa 71 - 305.
doi:10.1371/journal.pone.0083062.g001
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likely as a result of a functional NLS1 (Figure 4C). We speculate
that under specific physiological conditions, cystin can cycle out of
the ciliary membrane and translocate into the nucleus to regulate
gene expression.
Cystin is co-localized with necdin in mIMCD-3 cells
In order to evaluate whether cystin and necdin co-localize in
mIMCD-3 cells, we created a cystin::GFP and necdin::RFP (red
mono) stable cell line. We found necdin in the cytoplasm and
largely in the nuclei of confluent mIMCD-3 cells (Figure 5, II and
V). Conversely, most of the cystin::GFP was found in the
cytoplasm while much less of it was in the nucleus (Figure 5, I).
Based on our previous studies, we predict that cystin can traffic
between the nucleus and cytoplasm [38]. Thus, a strategy to verify
this hypothesis was to block nuclear export, thereby retaining any
cystin that did enter the nucleus. We used the nuclear export
inhibitor leptomycin B, upon optimization we found that 80 nM
was effective at causing cystinG2A::GFP nuclear retention (Figure
5, IV). Consistent with our hypothesis, cystin visibly accumulated
in the nucleus and co-localized with necdin (Figure 5, V). This
observation suggests that cystin can translocate from the cilia and/
or cytoplasm into the nucleus and is in a position to complex with
necdin to function therein.
Cystin antagonizes necdin to modulate Myc P1 promoter
activity
Cystin is a small protein that has no readily identifiable DNA
binding domain as determined by bioinformatic analysis, suggest-
ing that for cystin to regulate gene expression, it would need to
interact with other transcriptional regulatory proteins, like necdin.
Therefore, we sought to determine whether these two proteins
interact to modulate Myc expression. It has been confirmed that c-
Myc is over expressed in cpk kidneys [43,44] and that necdin
activates the Myc expression through binding to its GN box in the
promoter [45]. Western blot data demonstrates that c-Myc is
highly expressed in the 14 day-old mutant cpk mouse compared to
a wild-type littermate (Figure 6A). The expression of Myc is
regulated by two major promoters, P1 and P2, with transcription
initiation sites 164 base pairs apart [46] (Figure 6B, upper map).
Interestingly, most of c-Myc overexpression results from dysreg-
ulation of the P1 promoter element [47]. Therefore, we cloned the
Myc P1 promoter, ranging from bp -88 to +47 (Figure 6B, lower
map), into a luciferase reporter vector and performed dual-
luciferase reporter assays (Figure 6C). Our data showed that in
mIMCD-3 cells, necdin activated the Myc P1 promoter (Figure
6C, lane 3), consistent with previously published data [45]. We
then tested the effect of cystin on Myc P1 promoter activity in
mIMCD-3 cells. Alone, cystin was able to significantly activate the
Figure 2. The interaction between cystin and necdin was further verified by GST pull-down and co-immunoprecipitation. (A) GST
pull-down was used to verify the interaction between cystin and necdin. pCMV-GST-cystin and pCMV-myc-necdin were co-transfected into COS-7
cells. The precipitated samples were run on a PAGE gel and probed with myc (lanes 1-4) and GST antibodies (lanes 5-8). Whole cell lysate was used to
assess protein expression (lane 1-2 and 5-6). Compared to the negative control (lane 3), the specific interaction between cystin and necdin is clear
(lane 4, arrowhead). (B) Co-IP was used to verify the interaction between cystin and necdin. pCMV-HA-cystin and pCMV-myc-necdin were co-
transfected into COS-7 cells. The protein complex of HA-cystin and myc-necdin in the cell lysate was precipitated using the HA tag, and the samples
were probed with myc (lanes 1-4) and cystin antibodies (lanes 5-8), respectively. Whole cell lysate was used to control for protein expression (lane 1-2
and 5-6). Compared with the negative control (lane 3), a specific band indicates a physical interaction between cystin and necdin (lane 4, arrowhead).
doi:10.1371/journal.pone.0083062.g002
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Figure 3. Endogenous cystin and necdin were expressed in mIMCD-3 cells. (A) RT-PCR was performed to detect the expression of cystin and
necdin in mIMCD-3 cells. Total RNA was isolated from confluent mIMCD-3 cells and equal amounts of cDNA were used as a template for RT-PCR.
Primer pairs for cystin and necdin were designed to amplify 207 bp and 632 bp target bands, respectively. b-actin was used as a positive control;
water was used as a negative control. The PCR products were excised from the gel, purified, and verified by sequencing (data not shown). (B) Western
blot analysis of endogenous cystin in confluent mIMCD-3 cells. The cells were fractioned to cytoplasmic, membrane, and nuclear fractions. Analysis of
control proteins for the different fractions were shown in the lower panel. Endogenous cystin migrates at 25 kDa and accumulated in the membrane
fraction. (C) Western blot analysis of endogenous necdin in confluent mIMCD-3 cells. Endogenous necdin was detected in the nuclear fraction and
migrated at 40 kD when probed with a necdin N-terminal antibody (N20, arrowhead). Western blot analysis of Myc-necdin in mIMCD-3 cells using a
myc antibody also reveals a band at 40 kD (right). The band at ,30 kDa is an unidentified artifact of the antibody used [103].
doi:10.1371/journal.pone.0083062.g003
Figure 4. Cystin has a functional nuclear localization signal at the N-terminus. The subcellular localization of cystin and its variants was
determined by immunoblotting. The wild-type cystinwt, the N-terminal deletion mutant cystinn1-20, and the site-directed mutant cystinG2A, each
tagged with GFP were stably-transfected in mIMCD-3 cells. (A) The distribution of wild-type cystinwt::GFP in the four fractions prepared from mIMCD-
3 cells is shown by western blot (above) and using densitometry (below). (B) The distribution for cystinn1-20::GFP is similarly shown by western and
densitometry. (C) The distribution of the site-directed mutant cystinG2A::GFP is shown in the four fractions of mIMCD-3 cells using western blot
analysis and densitometry. (D) To demonstrate the reliability of the fractionation protocol, wild type mIMCD-3 cells were fractionated (n = 5
experiments) and 10 mg of each fraction was analyzed by western blotting with fraction specific marker as indicated. The fractions are cytosol (1),
membrane (2), nuclear (3) and cytoskeleton (4).
doi:10.1371/journal.pone.0083062.g004
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Myc P1 promoter (Figure 6C, lane 4), and intriguingly, the necdin-
interaction deficient version of cystin (-C25 construct) also
activated the P1 promoter (Figure 6C, lane 5). The magnitude
of stimulation by necdin (1.5 fold) was greater than that of cystin
(0.5 fold). Importantly however, when in co-transfection assays,
cystin antagonized the activity of necdin, resulting in activation
levels similar to that of cystin alone (Figure 6C, lane 6). Further, we
found that the cystin modulation of necdin-associated Myc P1
promoter activity was dependent on the necdin-binding domain in
the cystin C-terminus. Necdin activation of the Myc P1 promoter
was not inhibited by the –C25 construct (Figure 6C, lane 7). These
data demonstrate that cystin and necdin can both activate the Myc
P1 promoter (albeit necdin has a more potent effect), and that
cystin antagonizes the stimulatory effect of necdin through a direct
protein-protein interaction. Taken together, our data indicate that
cystin is a key modulator of c-Myc expression.
Both cystin and necdin bind to Myc P1 DNA
Our reporter assay data in mIMCD-3 cells suggested that
necdin and cystin function together to regulate the Myc P1
promoter, but whether this was through directly binding the DNA
is unknown. ChIP experiments were used to assess the interaction
between the Myc P1 DNA and the necdin and cystin proteins. We
co-transfected Myc P1, myc-necdin, HA-cystin, or HA-cystin-C25
in various combinations into COS-7 cells. Western blots
confirmed that myc-necdin, HA-cystin, and HA-cystin-C25 were
all highly expressed in COS-7 cells, and the antibodies used for IP
were specific to the proteins expressed (Figure 7C). After
immunoprecipitation with antibodies against cystin or necdin,
we performed PCR with specific primers spanning the full-length
Myc P1 promoter to amplify any bound Myc P1 DNA (Figure 7A).
The results indicate that necdin (Figure 7B, lanes 2, 3, 5), cystin
(Figure 7B, lanes 3, 4), as well as cystin (C-25) (Figure 7B, lanes 5,
6) immunoprecipitated with the Myc P1 DNA fragment. This data,
together with the luciferase data (Figure 6C), further suggests that
cystin can bind the Myc P1 promoter without necdin.
In order to confirm that cystin and necdin can bind to the Myc
P1 promoter DNA, we performed an electrophoretic mobility shift
assay (EMSA). To ensure that the samples used for the EMSA
experiments were biologically relevant, we used nuclear extracts
from mIMCD-3 cells that had been transfected with myc-necdin,
HA-cystin, or an empty vector, respectively. We used 59 biotin-
labeled oligonucleotides that contained the Myc P1 GN box as a
probe (–50,–28) (Figure 7A, right side map). The shifted DNA-
protein complexes were readily observed in the mixtures
containing transfected necdin or cystin and the labeled GN box
probe (Figure 7D, lanes 3, 5). As controls, the empty vector
mIMCD-3 extract did not show any shifted band, and unlabeled
probe was able to compete and abolish the interaction (Figure 7D,
lanes 2, 4, 6). Expression of cystin or necdin in the nuclear input
was confirmed (Figure 7E). Combined with our reporter assay,
both the ChIP and EMSA data confirm that both cystin and
necdin interact with the Myc P1 promoter fragment and likely
function as a regulatory complex modulating Myc expression.
Discussion
In this study, we employed a Y2H approach using a full-length
cystin construct to screen a mouse embryo cDNA library for
cystin-interacting partners under stringent selection conditions
(SD/-Ade/-His/-Leu/-Trp/X-gal). Necdin was among the puta-
tive interacting partners identified in this screen. Subsequently, the
physical interaction of these two proteins was confirmed by GST
pull-down and co-immunoprecipitation, and is supported by
immunofluorescent experiments showing colocalization of the
proteins at the subcellular level. From the perspective of renal
cystic epithelia biology, necdin is an interesting cystin binding
partner. Necdin was first identified in mouse stem cells of
embryonic carcinoma origin [48] and has been detected in the
nucleus of differentiated neuronal cells, but not in undifferentiated
cells [49–54]. Further, necdin has been identified as a maternally
imprinted gene and is implicated as a disease-causing gene
associated with Prader-Willi syndrome [49,55,56]. Necdin is a
DNA-binding protein [57] that binds to the GN box of the Myc P1
promoter and regulates its activity [45]. The N-terminus of necdin
is proline-rich, which is a typical feature of trans-activation/
repression domains of transcription factors [58,59]. In addition,
necdin has more recently been linked to p53 signaling, histone
acetylation, calcium signaling, and interacts with multiple tran-
scription factors (e.g. Dlx5, SIM1, and Msx2) [51,53,60–63].
To date, a number of interacting partners of necdin have been
identified, some of which are renal cystic disease-related proteins,
including Bbs4, HIF1a, p53, and E2F1 [50,61,64,65]. Bbs4 is
encoded by one of the causative genes of Bardet-Biedl syndrome
(BBS), an inherited ciliopathy characterized by renal cystic disease,
obesity, polydactyly, and diverse neuropsychiatric symptoms
[66,67]. Further, deficiencies in p53, a well-known tumor
suppressor, are associated with a renal cystic phenotype during
embryonic development [68]. Necdin also appears to mediate the
degradation of hypoxia-inducible factor 1 alpha (HIF1a), whose
overexpression is involved in renal cyst formation [69,70]. In post-
mitotic neurons, necdin acts as an anti-apoptotic factor by
repressing E2F1-dependent Cdc2 transcription, thus stabilizing
neuronal terminal differentiation [71]. While necdin is associated
with multiple renal cystic disease-related genes, a kidney pheno-
type in necdin mutant mouse models has not been well studied
[63].
The proto-oncogene c-Myc was first discovered in Burkitt’s
lymphoma patients [72]. It is a basic Helix-Loop-Helix/Leucine
Zipper transcription factor that binds to enhancer box sequences
(E-box: CACGTG) and recruit histone acetyltransferases to
transcriptionally regulate the expression of 15% of all genes,
Figure 5. Exogenous cystin and necdin were co-localized in
mIMCD-3 cells. A stable cell line transfected with both cystin::GFP and
necdin::RFP, was established in mIMCD-3 cells. Under identical
conditions, the co-localization of cystin and necdin was determined
with and without leptomycin B (LMB) treatment. As shown by
epifluorescence, in confluent mIMCD-3 cells, cystin::GFP was primarily
retained in the cytoplasm, while necdin::RFP was mainly distributed in
the nucleus (I-III). Cystin and necdin only minimally co-localize in the
cytoplasm. After LMB treatment (80 nM, 5 hrs lower panels, IV-VI),
cystin::GFP was retained in the nucleus and co-localized with necdin (V,
white dashed oval).
doi:10.1371/journal.pone.0083062.g005
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including genes involved in growth, proliferation, cell cycle
progression, apoptosis, and differentiation [73]. Dysregulated
expression of c-Myc contributes to the genesis of multiple types
of human tumors [74] and targeting Myc overexpression in stenosis
is the focus of current clinical trials (http://clinicaltrials.gov/ct2/
show/study/NCT00777842; National Institutes of Health.
Bethesda, MD) [75]. The mechanisms that govern Myc transcrip-
tion are complex and involve multiple promoters (P0, P1, P2, and
P3) and start sites. As noted above, the P1 and P2 promoters are
the predominant Myc regulatory elements and most ectopic Myc
expression results from dysregulation at the P1 promoter.
Overexpression of Myc, a common feature of PKD, was first
described in cpk kidneys [43,44]. Presently, it is thought that c-Myc
overexpression is a hallmark of PKD and cystogenesis in general
[76–86]. Mouse and pig transgenic models designed to overex-
press c-Myc manifest a PKD-like renal phenotype [87,88]. Of
additional note, a newly identified variant myc-Nick is associated
with microtubule hyperacetylation [89], a characteristic of renal
cystic epithelia [90]. Further, alterations in c-Myc expression have
led to speculation about the possible role for cilia and cilia-related
genes in the modulation of Wnt and Hippo signaling [81,91–93].
Interestingly, the necdin-interacting partners mentioned above,
including HIF1a, p53, and E2F1 have also been shown to be
targets of c-Myc [94–97]. In addition, other renal cystic disease-
related genes, adenomatosis polyposis coli (APC) and Von Hippel-
Lindau (VHL) are also directly targeted by c-Myc [94,98,99].
Perhaps most importantly, a study by Ricker et al. used Myc
antisense oligonucleotides to successfully attenuate the ARPKD
phenotype in cpk mice [100]. These reports support the hypothesis
that upregulation of Myc is a significant cystogenic factor in cpk
kidneys.
In this study we demonstrate that cystin and necdin interact as a
complex with the P1 promoter to regulate Myc expression. Our
data show that necdin enhances Myc promoter activity and that
cystin antagonizes this effect. These data are consistent with in vivo
observations that Myc is overexpressed in cpk kidneys and anti-Myc
nucleotides mitigate the cystic kidney phenotype [100]. Impor-
tantly, we noted that there was significant variability in the
luciferase assays when veteran mIMCD-3 cells (.50 passages)
were used, suggesting that necdin and cystin have dynamic effects
on gene expression that depends at least in part on the age of the
cell line. Using low passage (,10) mIMCD-3 cells (American Type
Culture Collection), our experimental data had much more
limited variability and strong reproducibility. Since both the N-
and C-termini of necdin are required for cystin interaction (Figure
1B, lower panel) and cystin C-25 does not inhibit the stimulatory
Figure 6. The activation effect of necdin on Myc P1 promoter activity is antagonized by cystin. (A) Immunoblot analysis of c-myc
expression in total kidney lysates from 14 day-old Cys1cpk/cpk (MUT) and wild-type (WT) mice, densitometry shown below. (B) Schematic structures of
the Myc P1 and P2 genomic promoter (upper) and the Myc P1 luciferase construct (lower) where Myc P1 DNA from –88 to +47 was cloned into
pGL4.22 vector. (C) Luciferase analysis of the effect of necdin and cystin on Myc P1 activity. Basal P1 activity (lane 2) is elevated ,1.5 fold by necdin
(lane 3) and to a lesser extent by cystin alone (lane 4). However, cystin abrogates the ability of necdin to activate the P1 element when co-transfected
(lane 6), as long as the necdin interacting domain remains intact [i.e. the –C25 mutant does not inhibit necdin (lane 7)]. Error bars represent the 95%
confidence interval for the SEM (p,0.05).
doi:10.1371/journal.pone.0083062.g006
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effect of necdin on the P1 promoter, we speculate that the
counteracting effect of cystin on necdin is likely dependent on the
interaction of these two proteins, which in turn impacts their
ability to bind DNA, transactivators, or other transcription factors.
Both cystin and necdin are expressed in the mIMCD-3 renal
cell line, as detected by RT-PCR and western blot. To our
knowledge, this is the first report of necdin expression in renal
epithelial cells. It has been reported that necdin is localized in the
nucleus, centrosome, and cytoplasm [50,51,101]. This distribution
pattern resembles that of cystin (and other cystoproteins), although
there is no evidence that necdin localizes to cilia. Thus, these two
proteins may play a role in the regulation of cell cycle and/or
centrosome duplication directly or indirectly through gene
regulation. This report adds to a growing dataset of ciliary
proteins with roles in mammalian gene expression (e.g. PC-1 and
FPC) [29,46,102].
In summary, our data indicate that cystin and necdin
independently bind to the Myc promoter, but their direct
interaction is required to properly regulate Myc expression. We
propose that Myc overexpression in the cpk mouse results directly
from the disruption of this cystin-necdin regulatory complex,
which allows necdin to aberrantly drive Myc expression. Based on
our data, and the observations of others, that Myc overexpression is
a common signature in cystic epithelia, we speculate that other
cystoproteins and/or their downstream effectors may be targets of
the cystin-necdin transcriptional regulatory complex.
Materials and Methods
Yeast two-hybrid screening
Cystin (full ORF, cloned into pGBKT7, the bait vector), was
used to screen the embryonic day 17 mouse embryo cDNA library
that was transformed into the Y187 yeast strain. The co-
transformants surviving on SD/-Ade/-His/-Leu/-Trp/X-gal se-
lection plates were positive candidates. To eliminate the false
positives, cystin was switched into the pGADT7 prey vector and
rescreened against the other putative interacting partners in the
pGBKT7 vector. Yeast Transformation System 2 (Clontech) and
the MATCHMAKER GAL4 Two-Hybrid System 3 (Clontech)
were used.
Figure 7. Both necdin and cystin bind to Myc P1 promoter DNA. (A) Schematic representation of the Myc P1 promoter (–88 , +47) fragment
in the pGL4.22 luciferase vector used for chromatin immunoprecipitation (ChIP). The ChIP primers (F and R) spanned the promoter region. The right
panel showes the 23-bp EMSA probe, containing the Myc P1 GN-box (underlined). (B) ChIP was performed to identify the interaction of necdin, cystin,
and cystin-C25 with the Myc P1 promoter fragment. After sonication, the protein-DNA complexes were immunoprecipitated either with the anti-
necdin (N143) or cystin (70053) antibody. (C) Western blot analysis confirmed that each of the constructs were highly expressed in the ChIP
experiments. HA-cystin/HA-cystin-C25 were detected with the anti-cystin antibodies (70053) and myc-necdin was detected with an anti-necdin
antibody (N143). (D) EMSA was performed to analyze the binding of necdin and cystin to the Myc P1 DNA fragment. The biotin-labeled probe (A right
panel) containing the Myc P1 GN box was incubated with nuclear extracts from mIMCD-3 cells transfected with wild-type cystin and necdin. Both
cystin and necdin bound to the Myc P1 GN box (lanes 3, 5) and this binding was efficiently abolished by unlabeled probe. (E) Immunoblotting
analysis of the EMSA samples indicated robust expression of HA-cystin and myc-necdin in nuclear extracts, histone H3 was used as a loading control.
doi:10.1371/journal.pone.0083062.g007
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GST pull-down assay
GST pull-downs were performed per the ProFound Pull-Down
GST Protein Interaction kit (Pierce). Both the cystin and necdin
were cloned into the pCMV-GST vector (eukaryotic GST fusion
vector) and the pCMV-myc vector, respectively. Briefly, 20 mg of
plasmid DNA were co-transfected into COS-7 cells in 10 cm
plates at 90% confluence with 30 ml Lipofectamine 2000
(Invitrogen). After ,48 hrs cell growth, the cells were washed
and lysed in 0.8 ml ProFound cell lysis buffer with proteinase
inhibitor (complete Mini, EDTA-free, Roche), and incubated at
4uC for 30 min. About 0.7 ml of supernatant was collected after
centrifugation. The cell lysates were incubated with 50 ml
immobilized glutathione beads (50% slurry, 25 ml bed volumes)
overnight on a rocking platform at 4 uC. After incubation, the
samples were centrifuged at 1300 g for 30 sec to 1 min to collect
GST protein complexes. The GST-glutathione beads were
vigorously washed with cold cell lysis buffer 5–6 times and
centrifuged. Finally, the protein/bead complex was eluted in
,200 ml 100 mM Glutathione in cell lysis buffer. The purified
proteins were subjected to western blot analysis with anti-GST
antibody (Santa Cruz #80998), anti-Myc antibody (Abcam
#ab32).
Co-immunoprecipitation
Cells were prepared as described above for the GST pull-
down assay, 350 ml of supernatant was transferred to co-
immunoprecipitation mini-spin columns (Pierce) with HA or
Myc antibody (Abcam #ab32) and incubated overnight with
gentle rotation at 4 uC. Then 50 ml of a 50% protein G agarose
slurry was added to the mixture and further incubated for 5 hrs
with rotation. The agarose-protein G/antibody/protein complex
was collected by centrifuging at 1300 g for 45,60 sec. The
agarose was washed vigorously 8 times with 400 ml washing buffer
(cell lysis buffer plus 0.2% NP40). The protein complex was eluted
with 30 ml elution buffer (PIERCE), mixed and centrifuged at
1300 g for 60 sec. The eluant was neutralized immediately by
adding 1 ml of 1 M Tris, pH 9.5 per 20 ml of elution buffer. This
step was repeated and the two eluates were pooled in one
collection tube. Samples were then prepared for analysis by
western blot with anti-Myc (Abcam #ab32), and anti-cystin ([38]
#70053).
RT-PCR
The RNeasy Mini Kit (QIAGEN) was used to isolate total RNA
from mouse mIMCD-3 cells and the Superscript First-strand
Synthesis System (Invitrogen) was used for cDNA synthesis. PCR
was then performed with the following primers:
for cystin 59-GTCCATGAATCCTCAGAACACAACC-39
(forward); and 59-CTCAGCCATTCGGTAGACACTC-39 (re-




Cystin::GFP ; necdin::RFP stable transformants were seeded
onto transwell tissue culture polyester membrane (Costar 3470 for
enface imaging) and cultured to 5 days beyond confluence. To block
nuclear export of cystin::GFP, stable cells were treated with 80 nM
leptomycin B (LMB) for 5 hrs. Cells were washed with PBS, fixed
with 4% para-formaldehyde, permeabilized with 0.2% Triton X-
100, washed with PBS and counterstained with Hoechst 33258.
The membrane was cut out and mounted with ProLong Gold
(Molecular Probes) on slides for enface imaging of the monolayer.
Fluorescently-labeled cells were analyzed on a Leica scanning laser
confocal microscope configured with both an Argon Ion (5 mW,
488 nm) and a Krypton Ion (10 mW, 568 nm) laser.
Luciferase Reporter assay
The core promoter sequence, Myc P1 (–88,+47) was cloned
into the firefly luciferase vector pGL4.22. Fresh (,5 passages)
mIMCD-3 (ATCC #CRL-2123) cells were seeded in 24-well
plates and grown to ,80–90% confluence, and then transfected
with various plasmids using Lipofectamine 2000. All samples
represented in Figure 6C were transfected with 15 ng of control
Renilla plasmid; lane 1 received 0.3 mg empty vector (pGL4) while
lanes 2–7 got 0.3 mg of pGL4.22-Myc P1. pcDNA 3.1 was used for
filler DNA in combination with pCMV-myc-necdin, pCMV-HA-
cystin, and pCMV-HA-cystin-C25 each used at 0.6 mg. Trans-
fected cells were incubated for 48 hrs and the cells were lysed in
100 ml passive lysis buffer (Promega) and shaken for 20 min at
room temperature. Firefly and Renilla luciferase activities were
measured with Dual Luciferase Reporter Assay System (Promega).
The luminometer (CENTRO LB 960 Microplate Luminometer,
running MikroWin, Version 4.41) was programmed to perform a
1-sec delay with agitation, followed by a 5-sec measurement period
for each reporter. 20 ml cell lysate was carefully transferred into
96-well plate, to which 100 ml Luciferase Assay Reagent II was
dispensed and luciferase activity was measured, followed by the
addition of 100 ml of Stop&Glo and the measurement of Renilla
activity. Data are from three independent transfections done in
triplicate on three separate occasions.
Statistical Analysis
In Figure 6C, we calculated the relative luciferase activity in
each assay after correcting for transfection differences using the
Renilla plasmid. Using triplicate readings from three independent
experiments, the data were normalized to lane 2 (pGL4.22-Myc
P1) and the SEM was calculated. The 95% confidence interval of
the SEM was calculated (SEM x 1.96) and is represented as error
bars. All tests were conducted using a 2-tailed type 1 error of 5%.
Chromatin Immunoprecipitation (ChIP) assay
The ChIP Assay was performed according to the instructions in
the ChIP assay kit (Upstate/Milipore). Plasmid DNA of pGL4.22-
Myc P1 (5 mg), pCMV-myc-necdin (10 mg), pCMV-HA-cystin
(10 mg), and pCMV-HA-cystin-C25 (10 mg) in different combina-
tions were transfected with Lipofectamine 2000 (30 ml for 2 mg
DNA) into COS-7 cells at 90%–95% confluency. 48 hrs after
transfection, the cells were fixed with 1% paraformaldehyde in
culture media, and incubated at 37 uC, 5% CO2 for 10 min. After
fixation, the cells were washed twice with cold 1x PBS buffer
containing a protease inhibitor (Sigma, 5 ml/10 ml PBS). The cells
were collected and centrifuged at 3000 rpm at 4uC for 5 min. The
cell pellet was lysed in 320 ml of SDS lysis buffer plus protease
inhibitors, and incubated on ice for 10 min. Sonication was
performed with Sonic Dismembrator-60, (power output 6) under
the conditions: 10 sec, 10 times with 1 min interval on ice. After
sonication, the cell supernatant was collected by centrifuging at
13000 rpm at 4 uC for 5 min and diluted 10-fold in ChIP dilution
buffer containing protease inhibitors. Up to 900 ml for each
reaction was pre-cleared with ,30 ml Salmon Sperm DNA/
protein A agarose (a 50% slurry) with rotation at 4uC for 1 hr. The
agarose was collected at 1000 g for 1min and the supernatant was
transferred to a new tube.
The antibodies: anti-cystin, (30 mg/ml, # 70053) or anti-necdin
(N143, 10 mg/ml, Abcam #ab18554) were added and the
mixtures were incubated overnight at 4uC with constant rotation,
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followed by the addition and continued incubation with 35 ml
Salmon Sperm DNA/protein A for 1.5 hrs with rotation to
capture the antibody/protein complex. The protein A agarose-
antibody/protein complex was pelleted at 1000 g for 1 min and
the supernatant was discarded. The protein A agarose/antibody/
protein complex was washed for 12 min each at 4uC with 1 ml low
salt buffer, high salt buffer, and finally Lithium chloride wash
buffer. Two final washes, each with 1 ml TE buffer were
performed at RT. Then, the protein A agarose/antibody/protein
complex was re-suspended in 250 ml fresh elution buffer (0.1 M
NaHCO3, 1% SDS) and incubated at room temperature for 15
min with rotation. The agarose beads were then spun down and
the supernatant was transferred into a new tube. This was
repeated and the two eluates (total volume ,500 ml) were
combined. 20 ml 5 M NaCl was added and the mixture was
incubated at 65 uC for 4 hrs or overnight to reverse cross-link the
DNA. Finally, 10 ml 0.5 M EDTA, 20 ml of 1 M Tris-HCl, pH 6.5
and ,20 mg proteinase K were added to the tube and incubated at
45uC for 1hr. DNA was recovered with 500 ml phenol/chloroform
(phenol:chloroform:IAA, pH 7.9, Ambion) and chloroform:IAA
(24:1) extraction. The upper layer was transferred to a new tube.
Then precipitation using 1/10 volume 3M sodium acetate
(pH 5.2), 40 mg glycogen as a DNA carrier, and a 2.5 volumes
ice-cold 100% ethanol was performed after incubation at –70uC
overnight. The DNA pellet was collected by centrifuge at 16100 g
for 10 min at 4uC. The supernatant was removed and the pellet
was washed with 1 ml 70% ethanol and air dried. The DNA was
dissolved in 30 ml ddH2O. Five ml was used as template for a 25 ml
PCR reaction. PCR conditions were: 94uC 3 min, 94uC 30 sec,
62uC 30 sec, 68uC 12 sec, repeat for 33 cycles, 68uC 5 min, 4uC
holding. The PCR forward primer was: 59-CCGCTCGAGGA-
GAGAGGTGGGGAAGGGAGAAAG-39 and the reverse primer
was: 59-CCCAAGCTTAGTGAGGCGAGTCGGACCCGGCA-
39.
Electrophoretic mobility shift assay (EMSA)
mIMCD-3 cells were transfected with pCMV-HA vector,
pCMV-cystin-HA, or pCMV-necdin-myc respectively. Nuclear
extracts were prepared from mIMCD-3 cells using ProteoExtract
Subcellular Proteome Extraction kit (Merck KGaA, Darmstadt,
Germany). The gel shift binding reaction was performed
according to the instructions of the LightShift Chemiluminescent
EMSA kit (Pierce). Binding reagents and conditions were: 200
fmol 59 biotin-labeled probe (synthesized from Integrated DNA
Technologies, Inc.), 4 pmol unlabelled competitor, 2 ml 10X
binding reaction buffer, 1 ml 1% NP40, 1 ml 1 M MgCl2, 1 ml
nuclear extract (1 mg/ml),1 ml dANdT (1 mg/ml, Sigma) a nonspe-
cific DNA competitor in a total volume of 20 ml. The binding
reaction was performed at RT for 20 min, then 5 ml 5X loading
buffer was added and mixed well. DNA-protein binding was
analyzed by electrophoresis using a 6% retardation gel (Invitrogen)
with 0.5X TBE buffer, at 100V for 70 min. After electrophoresis,
the DNA-protein complex was transferred to Nylon membrane
(pre-soaked in 0.5X TBE for 20 min) using 0.5X TBE (pre-cooled
to ,10uC) buffer. When the transfer was complete, the membrane
was placed DNA side up on a dry paper towel and immediately
cross-linked for 1-2 minutes using the auto cross-link function of
the UV Stratalinker 2400 (Stratagene Inc.). After cross-linking, the
biotin-labeled DNA was detected with the Chemiluminescent
Nucleic Acid Detection Module (Pierce) following the manufac-
turer’s instructions.
Antibodies
Necdin (N20), Santa Cruz, #18255; Nedcin (N143 for ChIP),
Abcam, #ab18554; Histone H3, Cell Signaling, #9717; Histone
H1, Santa Cruz, #10806; Calpain-2, Cell Signaling, #2539;
pCadherin, Santa Cruz, #7893; Cytokeratin cocktail, Oncogene,
#CP68; Myc, clone generated at UAB, #9E10; HA, covance,
#MMS-101P; c-Myc, Cell Signaling, #5605.
Acknowledgments
The authors thank Amber K. O’Connor, PhD of akoWriting LLC for
editorial and figure design services, in addition Susan A. Lyons, PhD, Naoe
Harafuji, PhD, and Jacob A. Watts are thanked for critical review of the
manuscript. Statistical consultation was provided by Robert C. McCarter,
ScD, Clinical and Translational Science Institute at the Children’s
National (Award UL1TR000075, NIH National Center for Advancing
Translational Sciences).
Author Contributions
Conceived and designed the experiments: LMGW MW CY. Performed
the experiments: MW CY BT SB. Analyzed the data: MW CY BT
LMGW. Contributed reagents/materials/analysis tools: SB. Wrote the
paper: MW CY LMGW.
References
1. Sharma N, Berbari NF, Yoder BK (2008) Ciliary dysfunction in developmental
abnormalities and diseases. Curr Top Dev Biol 85: 371–427.
2. Gabow PA (1993) Autosomal dominant polycystic kidney disease. N Engl J
Med 329: 332–342.
3. Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney
disease. Lancet 369: 1287–1301.
4. Grantham JJ (2008) Clinical practice. Autosomal dominant polycystic kidney
disease. N Engl J Med 359: 1477–1485.
5. Berget SM (1995) Exon recognition in vertebrate splicing. J Biol Chem 270:
2411–2414.
6. Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, et al. (1996) Linkage,
clinical features, and prognosis of autosomal dominant polycystic kidney disease
types 1 and 2. J Am Soc Nephrol 7: 2142–2151.
7. Watnick T, Germino GG (1999) Molecular basis of autosomal dominant
polycystic kidney disease. Seminars in Nephrology 19: 327–343.
8. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, et al. (1996)
PKD2, a gene for polycystic kidney disease that encodes an integral membrane
protein. Science 272: 1339–1342.
9. Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, et al. (1995) The polycystic
kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell
recognition domains. Nat Genet 10: 151–160.
10. Van Adelsberg JS, Frank D (1995) The PKD1 gene produces a developmen-
tally regulated protein in mesenchyme and vasculature. Nat Med 1: 359–364.
11. Harris PC (1999) Autosomal dominant polycystic kidney disease: clues to
pathogenesis. Hum Mol Genet 8: 1861–1866.
12. Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, et al. (2006) Clinical
and molecular characterization defines a broadened spectrum of autosomal
recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 85: 1–21.
13. Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, et al. (2006)
Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary
mechanosensation and is activated in polycystic kidney disease. Dev Cell 10:
57–69.
14. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, et al. (2003) Polycystins
1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat
Genet 33: 129–137.
15. Zerres K, Mucher G, Becker J, Steinkamm C, Rudnik-Schoneborn S, et al.
(1998) Prenatal diagnosis of autosomal recessive polycystic kidney disease
(ARPKD): molecular genetics, clinical experience, and fetal morphology.
American Journal of Medical Genetics 76: 137–144.
16. Guay-Woodford LM, Desmond RA (2003) Autosomal recessive polycystic
kidney disease: the clinical experience in North America. Pediatrics 111: 1072–
1080.
17. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, et al. (2002) The gene
mutated in autosomal recessive polycystic kidney disease encodes a large,
receptor-like protein. Nat Genet 30: 259–269.
18. Bergmann C, Senderek J, Kupper F, Schneider F, Dornia C, et al. (2004)
PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD).
Hum Mutat 23: 453–463.
A Cystin-Necdin Complex Regulates Myc Expression
PLOS ONE | www.plosone.org 10 December 2013 | Volume 8 | Issue 12 | e83062
19. Yamada T, Terada Y, Homma MK, Nonoguchi H, Sasaki S, et al. (1995) AVP
inhibits EGF-stimulated MAP kinase cascade in Madin-Darby canine kidney
cells. Kidney Int 48: 745–752.
20. Bergmann C, Senderek J, Windelen E, Kupper F, Middeldorf I, et al. (2005)
Clinical consequences of PKHD1 mutations in 164 patients with autosomal-
recessive polycystic kidney disease (ARPKD). Kidney Int 67: 829–848.
21. Denamur E, Delezoide AL, Alberti C, Bourillon A, Gubler MC, et al. (2010)
Genotype-phenotype correlations in fetuses and neonates with autosomal
recessive polycystic kidney disease. Kidney Int 77: 350–358.
22. Gunay-Aygun M, Tuchman M, Font-Montgomery E, Lukose L, Edwards H, et
al. (2010) PKHD1 sequence variations in 78 children and adults with
autosomal recessive polycystic kidney disease and congenital hepatic fibrosis.
Mol Genet Metab 99: 160–173.
23. Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman M, Graf J, et al.
(2010) Correlation of kidney function, volume and imaging findings, and
PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney
disease. Clin J Am Soc Nephrol 5: 972–984.
24. Ong AC, Wheatley DN (2003) Polycystic kidney disease--the ciliary
connection. Lancet 361: 774–776.
25. Lina F, Satlinb LM (2004) Polycystic kidney disease: the cilium as a common
pathway in cystogenesis. Curr Opin Pediatr 16: 171–176.
26. Ibraghimov-Beskrovnaya O, Bukanov N (2008) Polycystic kidney diseases: from
molecular discoveries to targeted therapeutic strategies. Cell Mol Life Sci 65:
605–619.
27. Edelstein CL (2008) Mammalian target of rapamycin and caspase inhibitors in
polycystic kidney disease. Clin J Am Soc Nephrol 3: 1219–1226.
28. Goilav B, Satlin LM, Wilson PD (2008) Pathways of apoptosis in human
autosomal recessive and autosomal dominant polycystic kidney diseases.
Pediatr Nephrol 23: 1473–1482.
29. Kim I, Fu Y, Hui K, Moeckel G, Mai W, et al. (2008) Fibrocystin/polyductin
modulates renal tubular formation by regulating polycystin-2 expression and
function. J Am Soc Nephrol 19: 455–468.
30. Wang S, Zhang J, Nauli SM, Li X, Starremans PG, et al. (2007) Fibrocystin/
polyductin, found in the same protein complex with polycystin-2, regulates
calcium responses in kidney epithelia. Mol Cell Biol 27: 3241–3252.
31. Wu Y, Dai XQ, Li Q, Chen CX, Mai W, et al. (2006) Kinesin-2 mediates
physical and functional interactions between polycystin-2 and fibrocystin. Hum
Mol Genet 15: 3280–3292.
32. Avner ED (1993) Renal developmental diseases. Seminars in Nephrology 13:
427–435.
33. Gattone VH, 2nd, MacNaughton KA, Kraybill AL (1996) Murine autosomal
recessive polycystic kidney disease with multiorgan involvement induced by the
cpk gene. Anat Rec 245: 488–499.
34. Ricker JL, Gattone VH, 2nd, Calvet JP, Rankin CA (2000) Development of
autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk mice. J Am
Soc Nephrol 11: 1837–1847.
35. Davisson MT, Guay-Woodford LM, Harris HW, D’Eustachio P (1991) The
mouse polycystic kidney disease mutation (cpk) is located on proximal
chromosome 12. Genomics 9: 778–781.
36. Fry JL, Jr., Koch WE, Jennette JC, McFarland E, Fried FA, et al. (1985) A
genetically determined murine model of infantile polycystic kidney disease. J
Urol 134: 828–833.
37. Hou X, Mrug M, Yoder BK, Lefkowitz EJ, Kremmidiotis G, et al. (2002)
Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of
polycystic kidney disease. J Clin Invest 109: 533–540.
38. Tao B, Bu S, Yang Z, Siroky B, Kappes JC, et al. (2009) Cystin localizes to
primary cilia via membrane microdomains and a targeting motif. J Am Soc
Nephrol 20: 2570–2580.
39. Yoder BK, Hou X, Guay-Woodford LM (2002) The polycystic kidney disease
proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal
cilia. J Am Soc Nephrol 13: 2508–2516.
40. Pierreux CE, Poll AV, Kemp CR, Clotman F, Maestro MA, et al. (2006) The
transcription factor hepatocyte nuclear factor-6 controls the development of
pancreatic ducts in the mouse. Gastroenterology 130: 532–541.
41. Hiesberger T, Shao X, Gourley E, Reimann A, Pontoglio M, et al. (2005) Role
of the hepatocyte nuclear factor-1beta (HNF-1beta) C-terminal domain in
Pkhd1 (ARPKD) gene transcription and renal cystogenesis. J Biol Chem 280:
10578–10586.
42. Hiesberger T, Bai Y, Shao X, McNally BT, Sinclair AM, et al. (2004) Mutation
of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and
produces renal cysts in mice. J Clin Invest 113: 814–825.
43. Cowley BD, Jr., Chadwick LJ, Grantham JJ, Calvet JP (1991) Elevated proto-
oncogene expression in polycystic kidneys of the C57BL/6J (cpk) mouse. J Am
Soc Nephrol 1: 1048–1053.
44. Harding MA, Gattone VH, 2nd, Grantham JJ, Calvet JP (1992) Localization of
overexpressed c-myc mRNA in polycystic kidneys of the cpk mouse. Kidney Int
41: 317–325.
45. Matsumoto K, Taniura H, Uetsuki T, Yoshikawa K (2001) Necdin acts as a
transcriptional repressor that interacts with multiple guanosine clusters. Gene
272: 173–179.
46. Albert T, Wells J, Funk JO, Pullner A, Raschke EE, et al. (2001) The chromatin
structure of the dual c-myc promoter P1/P2 is regulated by separate elements. J
Biol Chem 276: 20482–20490.
47. Hu HM, Kanda K, Zhang L, Boxer LM (2007) Activation of the c-myc p1
promoter in Burkitt’s lymphoma by the hs3 immunoglobulin heavy-chain gene
enhancer. Leukemia 21: 747–753.
48. Maruyama K, Usami M, Aizawa T, Yoshikawa K (1991) A novel brain-specific
mRNA encoding nuclear protein (necdin) expressed in neurally differentiated
embryonal carcinoma cells. Biochem Biophys Res Commun 178: 291–296.
49. Sutcliffe JS, Han M, Christian SL, Ledbetter DH (1997) Neuronally-expressed
necdin gene: an imprinted candidate gene in Prader-Willi syndrome. Lancet
350: 1520–1521.
50. Lee S, Walker CL, Karten B, Kuny SL, Tennese AA, et al. (2005) Essential role
for the Prader-Willi syndrome protein necdin in axonal outgrowth. Hum Mol
Genet 14: 627–637.
51. Taniguchi N, Taniura H, Niinobe M, Takayama C, Tominaga-Yoshino K, et
al. (2000) The postmitotic growth suppressor necdin interacts with a calcium-
binding protein (NEFA) in neuronal cytoplasm. J Biol Chem 275: 31674–
31681.
52. Takazaki R, Nishimura I, Yoshikawa K (2002) Necdin is required for terminal
differentiation and survival of primary dorsal root ganglion neurons. Exp Cell
Res 277: 220–232.
53. Liu X, Wang Y, Zhang Y, Zhu W, Xu X, et al. (2009) Nogo-A inhibits necdin-
accelerated neurite outgrowth by retaining necdin in the cytoplasm. Mol Cell
Neurosci 41: 51–61.
54. Hayashi Y, Matsuyama K, Takagi K, Sugiura H, Yoshikawa K (1995) Arrest of
cell growth by necdin, a nuclear protein expressed in postmitotic neurons.
Biochem Biophys Res Commun 213: 317–324.
55. Jay P, Rougeulle C, Massacrier A, Moncla A, Mattei MG, et al. (1997) The
human necdin gene, NDN, is maternally imprinted and located in the Prader-
Willi syndrome chromosomal region. Nat Genet 17: 357–361.
56. MacDonald HR, Wevrick R (1997) The necdin gene is deleted in Prader-Willi
syndrome and is imprinted in human and mouse. Hum Mol Genet 6: 1873–
1878.
57. Maruyama E (1996) Biochemical characterization of mouse brain necdin.
Biochem J 314 ( Pt 3): 895–901.
58. de Caestecker MP, Yahata T, Wang D, Parks WT, Huang S, et al. (2000) The
Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcrip-
tional activation domain. J Biol Chem 275: 2115–2122.
59. Zhu J, Zhang S, Jiang J, Chen X (2000) Definition of the p53 functional
domains necessary for inducing apoptosis. J Biol Chem 275: 39927–39934.
60. Lafontaine J, Rodier F, Ouellet V, Mes-Masson AM (2012) Necdin, a p53-
target gene, is an inhibitor of p53-mediated growth arrest. PLoS One 7:
e31916.
61. Taniura H, Matsumoto K, Yoshikawa K (1999) Physical and functional
interactions of neuronal growth suppressor necdin with p53. J Biol Chem 274:
16242–16248.
62. Hasegawa K, Yoshikawa K (2008) Necdin regulates p53 acetylation via
Sirtuin1 to modulate DNA damage response in cortical neurons. J Neurosci 28:
8772–8784.
63. Chapman EJ, Knowles MA (2009) Necdin: a multi functional protein with
potential tumor suppressor role? Mol Carcinog 48: 975–981.
64. Moon HE, Ahn MY, Park JA, Min KJ, Kwon YW, et al. (2005) Negative
regulation of hypoxia inducible factor-1alpha by necdin. FEBS Lett 579: 3797–
3801.
65. Taniura H, Taniguchi N, Hara M, Yoshikawa K (1998) Necdin, a postmitotic
neuron-specific growth suppressor, interacts with viral transforming proteins
and cellular transcription factor E2F1. J Biol Chem 273: 720–728.
66. Kim JC, Badano JL, Sibold S, Esmail MA, Hill J, et al. (2004) The Bardet-Biedl
protein BBS4 targets cargo to the pericentriolar region and is required for
microtubule anchoring and cell cycle progression. Nat Genet 36: 462–470.
67. Moore SJ, Green JS, Fan Y, Bhogal AK, Dicks E, et al. (2005) Clinical and
genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year
prospective, population-based, cohort study. Am J Med Genet A 132: 352–360.
68. Saifudeen Z, Dipp S, El-Dahr SS (2002) A role for p53 in terminal epithelial
cell differentiation. J Clin Invest 109: 1021–1030.
69. Pollard PJ, Spencer-Dene B, Shukla D, Howarth K, Nye E, et al. (2007)
Targeted inactivation of fh1 causes proliferative renal cyst development and
activation of the hypoxia pathway. Cancer Cell 11: 311–319.
70. Konda R, Sugimura J, Sohma F, Katagiri T, Nakamura Y, et al. (2008) Over
expression of hypoxia-inducible protein 2, hypoxia-inducible factor-1alpha and
nuclear factor kappaB is putatively involved in acquired renal cyst formation
and subsequent tumor transformation in patients with end stage renal failure. J
Urol 180: 481–485.
71. Kurita M, Kuwajima T, Nishimura I, Yoshikawa K (2006) Necdin
downregulates CDC2 expression to attenuate neuronal apoptosis. J Neurosci
26: 12003–12013.
72. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, et al. (1982) Translocation of
the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt
lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79:
7837–7841.
73. Gearhart J, Pashos EE, Prasad MK (2007) Pluripotency redux—advances in
stem-cell research. N Engl J Med 357: 1469–1472.
74. Herold S, Herkert B, Eilers M (2009) Facilitating replication under stress: an
oncogenic function of MYC? Nat Rev Cancer 9: 441–444.
75. Gustafson WC, Weiss WA (2010) Myc proteins as therapeutic targets.
Oncogene 29: 1249–1259.
A Cystin-Necdin Complex Regulates Myc Expression
PLOS ONE | www.plosone.org 11 December 2013 | Volume 8 | Issue 12 | e83062
76. Perez I, Lin CH, McAfee JG, Patton JG (1997) Mutation of PTB binding sites
causes misregulation of alternative 3’ splice site selection in vivo. Rna 3: 764–
778.
77. Yeo G, Hoon S, Venkatesh B, Burge CB (2004) Variation in sequence and
organization of splicing regulatory elements in vertebrate genes. Proc Natl
Acad Sci U S A 101: 15700–15705.
78. Yeo GW, Van Nostrand E, Holste D, Poggio T, Burge CB (2005) Identification
and analysis of alternative splicing events conserved in human and mouse. Proc
Natl Acad Sci U S A 102: 2850–2855.
79. Burn TC, Connors TD, Klinger KW, Landes GM (1995) Increased exon-
trapping efficiency through modifications to the pSPL3 splicing vector. Gene
161: 183–187.
80. Williams SS, Cobo-Stark P, James LR, Somlo S, Igarashi P (2008) Kidney
cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal
recessive polycystic kidney disease. Pediatr Nephrol 23: 733–741.
81. Bakeberg JL, Tammachote R, Woollard JR, Hogan MC, Tuan HF, et al.
(2011) Epitope-tagged Pkhd1 tracks the processing, secretion, and localization
of fibrocystin. J Am Soc Nephrol 22: 2266–2277.
82. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, et al. (2011) A
conditional knockout resource for the genome-wide study of mouse gene
function. Nature 474: 337–342.
83. Ramirez-Solis R, Liu P, Bradley A (1995) Chromosome engineering in mice.
Nature 378: 720–724.
84. Valenzuela DM, Murphy AJ, Frendewey D, Gale NW, Economides AN, et al.
(2003) High-throughput engineering of the mouse genome coupled with high-
resolution expression analysis. Nat Biotechnol 21: 652–659.
85. Cleary MA, van Raamsdonk CD, Levorse J, Zheng B, Bradley A, et al. (2001)
Disruption of an imprinted gene cluster by a targeted chromosomal
translocation in mice. Nat Genet 29: 78–82.
86. Smith AJ, De Sousa MA, Kwabi-Addo B, Heppell-Parton A, Impey H, et al.
(1995) A site-directed chromosomal translocation induced in embryonic stem
cells by Cre-loxP recombination. Nat Genet 9: 376–385.
87. Trudel M, Barisoni L, Lanoix J, V DA (1998) Polycystic kidney disease in SBM
transgenic mice: role of c-myc in disease induction and progression. American
Journal of Pathology 152: 219–229.
88. Ye J, He J, Li Q, Feng Y, Bai X, et al. (2013) Generation of c-Myc transgenic
pigs for autosomal dominant polycystic kidney disease. Transgenic Res.
89. Conacci-Sorrell M, Ngouenet C, Eisenman RN (2010) Myc-nick: a cytoplasmic
cleavage product of Myc that promotes alpha-tubulin acetylation and cell
differentiation. Cell 142: 480–493.
90. Berbari NF, Sharma N, Malarkey EB, Pieczynski JN, Boddu R, et al. (2012)
Microtubule modifications and stability are altered by cilia perturbation and in
cystic kidney disease. Cytoskeleton (Hoboken).
91. Gerdes JM, Katsanis N (2008) Chapter 7 ciliary function and wnt signal
modulation. Curr Top Dev Biol 85: 175–195.
92. Simons M, Gloy J, Ganner A, Bullerkotte A, Bashkurov M, et al. (2005)
Inversin, the gene product mutated in nephronophthisis type II, functions as a
molecular switch between Wnt signaling pathways. Nat Genet 37: 537–543.
93. Habbig S, Bartram MP, Muller RU, Schwarz R, Andriopoulos N, et al. (2011)
NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J
Cell Biol 193: 633–642.
94. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, et al. (2003) Genomic
targets of the human c-Myc protein. Genes Dev 17: 1115–1129.
95. Sears R, Ohtani K, Nevins JR (1997) Identification of positively and negatively
acting elements regulating expression of the E2F2 gene in response to cell
growth signals. Mol Cell Biol 17: 5227–5235.
96. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V (1993) c-Myc trans-
activates the p53 promoter through a required downstream CACGTG motif.
Cell Growth Differ 4: 57–65.
97. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR (1997) Myc and Ras
collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature
387: 422–426.
98. O’Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, et al. (2003) A
large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol
Chem 278: 12563–12573.
99. Born TL, Frost JA, Schonthal A, Prendergast GC, Feramisco JR (1994) c-Myc
cooperates with activated Ras to induce the cdc2 promoter. Mol Cell Biol 14:
5710–5718.
100. Matsumura H, Tada M, Otsuji T, Yasuchika K, Nakatsuji N, et al. (2007)
Targeted chromosome elimination from ES-somatic hybrid cells. Nat Methods
4: 23–25.
101. Kuwako K, Taniura H, Yoshikawa K (2004) Necdin-related MAGE proteins
differentially interact with the E2F1 transcription factor and the p75
neurotrophin receptor. J Biol Chem 279: 1703–1712.
102. Calvet JP (1998) MOLECULAR GENETICS OF POLYCYSTIC KIDNEY
DISEASE [Review]. Journal of Nephrology 11: 24–34.
103. De Camilli P, Moretti M, Donini SD, Walter U, Lohmann SM (1986)
Heterogeneous distribution of the cAMP receptor protein RII in the nervous
system: evidence for its intracellular accumulation on microtubules, microtu-
bule-organizing centers, and in the area of the Golgi complex. J Cell Biol 103:
189–203.
A Cystin-Necdin Complex Regulates Myc Expression
PLOS ONE | www.plosone.org 12 December 2013 | Volume 8 | Issue 12 | e83062
